PDCD1 and melanoma: Anti–PD-1 immunotherapy, although effective against some melanomas, can also exacerbate psoriasis and colitis (Tanaka et al., 2017), but IL-17A blockade may reverse these toxicities (Esfahani and Miller, 2017; Johnson et al., 2019).